男性及非妊娠女性骨髓水肿综合征/一过性骨质疏松症各种治疗方式的比较:一项系统综述
该系统综述纳入36篇文章共880例患者,比较双膦酸盐、伊洛前列素、髓芯减压、体外冲击波疗法及保守治疗对骨髓水肿综合征/一过性骨质疏松症的疼痛缓解和骨髓水肿消退效果,结果显示不同时间点各治疗方式各有优势,但现有研究可靠性低,需进一步大型多中心随机对照试验及标准化评分以形成循证推荐。
要点
- 双膦酸盐在<1个月疼痛缓解上优于髓芯减压,伊洛前列素在1-3个月优于双膦酸盐和髓芯减压。
- 3-6个月时双膦酸盐、伊洛前列素和髓芯减压疼痛缓解效果相当;6-12个月时髓芯减压和体外冲击波疗法效果优良。
- MRI上1-3个月双膦酸盐、伊洛前列素和髓芯减压骨髓水肿消退效果相近,保守组最不理想。
核心结论
- 骨髓水肿综合征/一过性骨质疏松症因高可靠性研究数量少,已被采用多种非标准化措施治疗。
- 当前文献显示在缩短骨髓水肿综合征/一过性骨质疏松症临床病程方面结果有前景,但需进一步大型多中心随机对照试验及标准化放射学和临床评分以获得循证治疗算法推荐。
研究设计与样本
- 系统综述,检索PubMed、Scopus、Cochrane和Google Scholar,由两位作者进行纳入和提取,采用改良Delphi技术、非随机研究方法学指数(MINORS)标准和Cochrane协作组偏倚风险工具进行方法学质量评估。
- 共纳入36篇文章,涉及880例患者。
主要发现
- 在<1个月疼痛缓解结局上,双膦酸盐效率高于髓芯减压;在1-3个月,伊洛前列素效率高于双膦酸盐和髓芯减压。
- 在3-6个月,双膦酸盐、伊洛前列素和髓芯减压三者疼痛缓解结果相同;在6-12个月,髓芯减压和体外冲击波疗法显示优良结果,随后是双膦酸盐和保守组(由非甾体抗炎药和/或镇痛药和/或限制负重组成)。
- 在1-3个月MRI上,双膦酸盐、伊洛前列素和髓芯减压对骨髓水肿消退结果相对相同,最不理想的是保守组。
- 在3-6个月,髓芯减压在骨髓水肿消退上似乎取得最佳结果,其次是体外冲击波疗法、保守组和双膦酸盐组。
- 在6-12个月,体外冲击波疗法与保守组、双膦酸盐组和伊洛前列素组相比结果最佳。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Transient osteoporosis (TO) or bone marrow edema syndrome (BMES) is a self-limited clinical condition, which affects middle-aged men and women. It can be treated with miscellaneous conservative and surgical measures, which are analyzed in this systematic review. INTRODUCTION: BMES/TO is a transient clinical entity, which can be treated with various therapeutic modalities. The aim of our study was to assess the efficacy of different therapeutic options for the alleviation of pain and reduction of bone marrow edema (BME) in patients with BMES/TO, as well as to propose a therapeutic algorithm. METHODS: PubMed, Scopus, Cochrane, and Google Scholar were searched. Eligibility and extraction of studies were conducted by two authors. Methodological quality assessment was carried out with the modified Delphi technique, Methodological Index for Non-Randomized Studies (MINORS) criteria, and Cochrane Collaboration's risk of bias tool. Outcomes that were compared were time of pain resolution, VAS pain scores, and BME regression on magnetic resonance imaging (MRI). RESULTS: A total of 36 articles (880 patients) were included. Bisphosphonates had higher efficiency in less than 1-month outcomes on pain resolution compared with core decompression (CD), while iloprost was more efficient at 1-3 months compared with bisphosphonates and CD. At 3-6 months, all three of the aforementioned showed equal results on pain resolution, and at a period of 6-12 months, CD and extracorporeal shockwave therapy (ESWT) showed excellent results followed by bisphosphonates and the conservative group (CG) consisting of non-steroidal anti-inflammatory drugs (NSAIDs) and/or analgesics and/or restricted weight bearing. On MRI at 1-3 months, bisphosphonates, iloprost, and CD had relatively the same outcomes on BME resolution, with the least promising being the CG. At 3-6 months, CD seemed to have achieved the best results on the resolution of BME, followed by ESWT, CG, and bisphosphonates group. At 6-12 months, ESWT had the best outcomes compared with the conservative, bisphosphonates, and iloprost groups. CONCLUSION: BMES/TO has been treated with many non-standardized measures due to the low number of highly reliable studies. Current literature shows promising results with regard to the reduction of the clinical course of BMES/TO, but further large multicenter randomized controlled trials, as well as standardized radiological and clinical scores, are warranted to acquire evidence-based recommendations on the therapeutic algorithm.
引用
- Paraskevopoulos K, Keskinis A, Vasios IS, et al. Comparison of various treatment modalities for the management of bone marrow edema syndrome/transient osteoporosis in men and non-pregnant women: a systematic review. Osteoporos Int. 2022. PMID: 36370218. doi:10.1007/s00198-022-06584-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。